Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Quince Therapeutics (Nasdaq: QNCX), a late-stage biotechnology company focusing on rare disease treatments, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's CEO and CMO, Dr. Dirk Thye, will engage in a fireside chat during this virtual event on Wednesday, February 12, 2025, at 2:00 p.m. Eastern Time.
Investors and interested parties can access the live webcast through the Events page in the News & Events section of Quince's Investor Relations website at ir.quincetx.com. A recording of the presentation will be made available shortly after the live event concludes.
Quince Therapeutics (Nasdaq: QNCX), un'azienda biotecnologica in fase avanzata focalizzata sui trattamenti per malattie rare, ha annunciato la sua prossima partecipazione alla 35ª Conferenza Annuale sulla Salute e le Scienze della Vita di Oppenheimer. Il CEO e CMO dell'azienda, Dr. Dirk Thye, prenderà parte a una chiacchierata informale durante questo evento virtuale che si terrà mercoledì 12 febbraio 2025, alle 14:00 ora orientale.
Investitori e parti interessate possono accedere alla diretta tramite la pagina Eventi nella sezione Notizie & Eventi del sito web delle Relazioni con gli Investitori di Quince all'indirizzo ir.quincetx.com. Una registrazione della presentazione sarà disponibile poco dopo la conclusione dell'evento dal vivo.
Quince Therapeutics (Nasdaq: QNCX), una empresa biotecnológica en etapa avanzada centrada en tratamientos para enfermedades raras, ha anunciado su próxima participación en la 35ª Conferencia Anual de Ciencias de la Vida y Salud de Oppenheimer. El CEO y CMO de la compañía, Dr. Dirk Thye, participará en una charla informal durante este evento virtual el miércoles 12 de febrero de 2025, a las 2:00 p.m. hora del Este.
Los inversores y las partes interesadas pueden acceder a la transmisión en vivo a través de la página de Eventos en la sección de Noticias y Eventos del sitio web de Relaciones con Inversores de Quince en ir.quincetx.com. Se pondrá a disposición una grabación de la presentación poco después de que concluya el evento en vivo.
Quince Therapeutics (Nasdaq: QNCX)는 희귀 질환 치료에 초점을 맞춘 후기 단계 생명공학 회사로, Oppenheimer 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여할 예정이라고 발표했습니다. 회사의 CEO이자 CMO인 Dr. Dirk Thye는 2025년 2월 12일 수요일, 동부 표준시 기준 오후 2:00에 이 가상 이벤트에서 파이어사이드 채팅에 참여할 것입니다.
투자자와 관심이 있는 분들은 Quince의 투자자 관계 웹사이트 ir.quincetx.com의 뉴스 및 이벤트 섹션의 이벤트 페이지를 통해 실시간 웹캐스트에 접속할 수 있습니다. 생중계가 종료된 직후 프레젠테이션의 녹음이 제공될 예정입니다.
Quince Therapeutics (Nasdaq: QNCX), une entreprise biopharmaceutique en phase avancée spécialisée dans les traitements des maladies rares, a annoncé sa prochaine participation à la 35e Conférence Annuelle sur la Santé et les Sciences de la Vie d'Oppenheimer. Le PDG et CMO de l'entreprise, Dr. Dirk Thye, participera à une discussion informelle lors de cet événement virtuel qui se déroulera mercredi 12 février 2025 à 14h00 heure de l'Est.
Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via la page Événements dans la section Actualités & Événements du site des Relations avec les Investisseurs de Quince à l'adresse ir.quincetx.com. Un enregistrement de la présentation sera mis à disposition peu après la fin de l'événement en direct.
Quince Therapeutics (Nasdaq: QNCX), ein Biotechnologieunternehmen in der späten Entwicklungsphase, das sich auf die Behandlung seltener Krankheiten konzentriert, hat seine bevorstehende Teilnahme an der 35. jährlichen Oppenheimer-Konferenz für Gesundheits- und Lebenswissenschaften bekannt gegeben. Der CEO und CMO des Unternehmens, Dr. Dirk Thye, wird an einem Fireside-Chat während dieser virtuellen Veranstaltung am Mittwoch, den 12. Februar 2025, um 14:00 Uhr Eastern Time teilnehmen.
Investoren und interessierte Parteien können das Live-Webcast über die Veranstaltungsseite im Bereich Nachrichten & Veranstaltungen auf der Investor Relations-Website von Quince unter ir.quincetx.com aufrufen. Eine Aufzeichnung der Präsentation wird kurz nach Abschluss der Live-Veranstaltung verfügbar sein.
- None.
- None.
A live webcast of the fireside chat will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.
About Quince Therapeutics
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205854544/en/
Media & Investor Contact:
Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com
Source: Quince Therapeutics, Inc.
FAQ
When is Quince Therapeutics (QNCX) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch Quince Therapeutics' (QNCX) Oppenheimer Conference presentation?
Will there be a replay available of QNCX's Oppenheimer Conference presentation?
What type of presentation will QNCX deliver at the Oppenheimer Healthcare Conference?
Who will represent Quince Therapeutics (QNCX) at the Oppenheimer Healthcare Conference?
